The issue at the center of this recall, which includes both the HeartMate II and HeartMate 3 LVAD, is the gradual buildup of biological materials. This can impact the device's performance, creating a heightened risk of injury or death.
Gregg Stone, MD, explains the details of the late-breaking REDUCE-HF trial at ACC.24, where an inter-atrial shunt improved symptoms in HFrEF, but not in HFpEF patients.
There is a rapidly growing shortage in general cardiologists and for positions in rural areas, numerous healthcare system recruiters set up at the ACC reported.
CMS has issued its proposed rule for the 2025 Medicare hospital inpatient prospective payment system, suggesting a payment increase of 2.6%. According to the American Hospital Association, this update would not be enough at a time when hospitals are already struggling to stay open.
Howard C. Herrmann, MD, principal investigator of the SMART trial, discussed his team's research on self-expanding vs. balloon-expandable TAVR valves in patients with small annuli.
A team of specialists from Cleveland Clinic reviewed nearly 3,000 medications, writing that a common type 2 diabetes medication offered the most potential as an effective treatment for AFib.
Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."
Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.
